Hebei Port, Pharscin Pharma, Xiamen Fig, Fujian Sunner and Sichuan Daily Press have all contributed to a $229m biomedicine fund raised by the private equity vehicle.
CICC Capital, the private equity arm of China-based investment bank China International Capital Corporation, has secured more than RMB1.6bn ($229m) from multiple corporates for a biomedicine fund, DealStreetAsia reported on Friday.
Port operator Hebei Port, pharmaceutical firm Pharscin Pharma, real estate services provider Xiamen Fig, poultry processor Fujian Sunner and Xinwen Venture Capital, the investment arm of newspaper publisher Sichuan Daily Press, are all among the limited partners for the fund.
The fund’s backers also include Huirong Qide Investment and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
